Clinical Trials in Texas

Showing 3921-3940 of 12,973 trials

Driving Rehabilitation and Innovation for Evaluating Risk in Post-Intensive Care Unit Survivors

NCT05999903

Older adults are at risk for ICU-acquired cognitive decline discernible from clinical, biological, and imaging- related changes in the brain following delirium and critical illness. Our Driving Rehabilitation and Innovation for Evaluating Risk in Post Intensive Care Unit Survivors (DRIVE-PICS) application seeks to implement in-vehicle kinematic driving data with neurocognitive assessments for essential formative work to develop data-based insights into driving behaviors. DRIVE-PICS is designed to contribute to a critical gap in health promotion to develop an evidence-based, in-vehicle driving assessment system to provide actionable driving safety data and rehabilitation strategies tailored to older ICU survivors, the participants' care partners, and clinicians.

DeliriumCritical IllnessDrive

Baylor Research Institute24 participantsStarted Sep 2023

Temple, Texas, United States

COMPLETED38 miles

Juvenile Idiopathic Arthritis (JIA) Registry

NCT00783510

This is a global registry, to evaluate the long-term safety of Humira® in patients with moderate to severe polyarticular Juvenile Idiopathic Arthritis (JIA), that are treated as recommended in the Humira® product label. Patients treated with MTX will be considered a reference group. Patients will be followed in both the Humira® and Methotrexate (MTX) arms for 10 years from the enrollment date into one of the treatment arms.

Juvenile Idiopathic ArthritisJIA

AbbVie849 participantsStarted Jul 2008

Phoenix, Arizona, United States • Tucson, Arizona, United States • Little Rock, Arkansas, United States +89 more locations

Driving Rehabilitation and Innovation for Evaluating Risk in Post-Intensive Care Unit Survivors

Juvenile Idiopathic Arthritis (JIA) Registry

Find Trials by Condition in Texas

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors

Framing Eighteen Coils in Cerebral Aneurysms Trial

myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD

Different Doses of Naronapride Vs. Placebo in Gastroparesis

Effectiveness and Safety of Princess FILLER Lidocaine in Correction of Nasolabial Folds (NLF)

Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children

Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer